FDA Approves LAMOTRIGINE EXTENDED-RELEASE — Par Health USA, LLC
Par Health USA, LLC received final FDA approval for the LAMOTRIGINE extended-release (ANDA201374), placing the company in direct competition with established mood-stabilizing therapies amid a shortage of brand-name products. This clearance to market a generic alternative is poised to alleviate supply constraints in the neuropsychiatric sector while exerting downward pressure on market prices for the medication.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed